Brief: Biomerica Announces CMS Medicare Payment Rate Of $300 For Revolutionary Infoods® IBS Test
23/12/2025 13:21
Dec 23 (Reuters) - Biomerica Inc BMRA.O: BIOMERICA ANNOUNCES CMS MEDICARE PAYMENT RATE OF $300 FOR REVOLUTIONARY INFOODS® IBS TEST BIOMERICA INC - $300 RATE APPLIES TO MEDICARE CLAIMS FROM JANUARY 2026 Source text: ID:nGNX3fYW26 Further company coverage: BMRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomerica
See all newsDiagnostics firm Biomerica's Q1 revenue drops on lower clinical lab orders
Brief: Biomerica May Offer Up To $250 Million Of Common Stock, Preferred Stock, Debt Securities, & Warrants
Brief: Biomerica Lands $1.75 Million CDMO Master Services Agreement For IVD Diagnostic Development
Biomerica's Q3 revenue falls, net loss widens on lower manufacturing sales
Brief: Biomerica Q3 Net Income USD -1.31 Million